NBM-BMX Administered Orally to Patients with Solid Tumors or Newly Diagnosed Glioblastoma
Status:
RECRUITING
Trial end date:
2029-09-30
Target enrollment:
Participant gender:
Summary
NBM-BMX is an orally available new chemical entity to inhibit histone deacetylases 8 (HDAC8) activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. This study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors or combination with the standard of care treatment in subjects with newly diagnosed glioblastoma.